Top

Archives of Gynecology and Obstetrics

Published in:

01-04-2012 | Short Communication

Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study

Authors: Enrique Teran, Fernando Briones, Verónica Nicolalde, Sandra Vivero, Peter Chedraui, Faustino R. Pérez-López

Published in: Archives of Gynecology and Obstetrics | Issue 4/2012

Abstract

Aim

To investigate the effect of intravenous hydralazine infusion on maternal nitric oxide (NO) levels.

Methods

This pilot study comprised 40 (n = 40) gestations complicated with severe preeclampsia to whom maternal plasma NO levels were determined by chemiluminescence before and after hydralazine administration. Blood pressure values were concomitantly assessed.

Results

After 20 min of intravenous hydralazine infusion blood pressure values decrease significantly in term and preterm gestations. This was accompanied by an overall significant decrease in mean plasma NO values (38.7 ± 12.9 to 35.4 ± 13.9 μmol/L, p < 0.05). Despite this, NO values decreased in 67.5% of cases (a 17.6% from baseline) and increased in 32.5% (a 14.8% from baseline) (p < 0.05 for both). Blood pressure decrease (%) was lower (systolic and diastolic) among those displaying a NO decrement than in the increment group. Interestingly, gestational age was higher in the group displaying decreased NO; however, this did not reach statistical significance (37.5 ± 2.7 vs. 35.9 ± 2.8 weeks, p = 0.08).

Conclusion

The results of this study fail to demonstrate a similar NO secretion after hydralazine infusion in women with severe preeclampsia.

Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17:511–531PubMedCrossRef

Pridjian G, Puschett JB (2002) Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv 57:619–640PubMedCrossRef

Friedman SA, Taylor RN, Roberts JM (1991) Pathophysiology of preeclampsia. Clin Perinatol 4:661–682

Powers RW, Catov JM, Bodnar LM, Gallaher MJ, Lain KY, Roberts JM (2008) Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome. Reprod Sci 15:374–381PubMedCrossRef

Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB (1994) The role of NO in the pathogenesis of preeclampsia. Am J Obstet Gynecol 171:944–948PubMed

Conrad K, Kerchner L, Mosher M (1999) Plasma and 24-h NOx and cGMP during normal pregnancy and preeclampsia in women on a reduced NOx diet. Am J Physiol 277:F48–F57PubMed

Begum S, Yamasaki M, Mochizuki M (1996) Urinary levels of nitric oxide metabolites in normal pregnancy and preeclampsia. J Obstet Gynaecol Res 22:551–559PubMed

Steinert JR, Wyatt AW, Poston L, Jacob R, Mann GE (2002) Preeclampsia is associated with altered Ca²⁺ regulation and NO production in human fetal venous endothelial cells. FASEB J 16:721–723PubMed

Chen LK, Huang CH, Yeh HM et al (2007) Polymorphisms in the endothelial nitric oxide synthase gene may be protective against preeclampsia in a Chinese population. Reprod Sci 14:175–181PubMedCrossRef

10.

Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F (2008) Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 34:957–963PubMed

11.

Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M (2010) Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 36:239–247PubMedCrossRef

12.

Teran E, Escudero C, Moya W (2006) Abnormal release of nitric oxide from nitrosoproteins during preeclampsia. Int J Gynecol Obstet 92:260–261CrossRef

13.

Teran E, Escudero C, Vivero S, Enriquez A, Calle A (2004) Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia. Hypertens Pregnancy 23:303–308PubMedCrossRef

14.

Diejomaoh FM, Omu AE, Al-Busiri et al (2004) Nitric oxide production is not altered in preeclampsia. Arch Gynecol Obstet 269:237–243PubMedCrossRef

15.

Giles TD (2006) Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 8(12 Suppl 4):2–16

16.

Tacchi D (1961) Peripheral vascular response to hydralazine in toxemia of pregnancy. Obstet Gynecol 18:300–304PubMed

17.

Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC; or the HYLA treatment study (2006) Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 128:157–162

18.

Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K (2005) Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 46:63–67PubMedCrossRef

19.

Magee LA, von Dadelszen P (2009) The management of severe hypertension. Semin Perinatol 33:138–142PubMedCrossRef

20.

Bauer JA, Fung HL (1991) Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 84:35–39PubMed

21.

Unger P, Berkenboom G, Fontaine J (1993) Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol 21:478–483PubMedCrossRef

22.

Münzel T, Kurz S, Rajagopalan S et al (1996) Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98:1465–1470PubMedCrossRef

23.

Thomas GR, DiFabio JM, Gori T, Parker JD (2007) Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 49:1289–1295PubMedCrossRef

24.

Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P (2003) Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327:955–965PubMedCrossRef

25.

Ellershaw DC, Gurney AM (2001) Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. Br J Pharmacol 134:621–631PubMedCrossRef

26.

Duley L, Meher S, Abalos E (2006) Management of pre-eclampsia. BMJ 332:463–468PubMedCrossRef

27.

Begum MR, Quadir E, Begum A, Akhter S, Rahman K (2002) Management of hypertensive emergencies of pregnancy by hydralazine bolus injection vs continuous drip: a comparative study. Medscape Women’s Health 7:1

28.

Lopez-Jaramillo P, Narvaez M, Calle A et al (1996) Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol 103:33–38PubMedCrossRef

29.

Echols M, Yancy C (2006) Isosorbide dinitrate hydralazine combination therapy in African American with heart failure. Vasc Health Risk Manag 2:423–431PubMedCrossRef

30.

Terán E, Racines-Orbe M, Vivero S, Escudero C, Molina G, Calle A (2003) Preeclampsia is associated with a decrease in plasma coenzyme Q10 levels. Free Radic Biol Med 35:1453–1456PubMedCrossRef

31.

Mata-Greenwood E, Chen DB (2008) Racial differences in nitric oxide-dependent vasorelaxation. Reprod Sci 15:9–25PubMedCrossRef

32.

Savvidou MD, Vallance PJT, Nicolaides KH, Hingorani AD (2001) Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 38:1289–1293PubMedCrossRef

33.

Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Endothelial nitric oxide synthase polymorphism in preeclampsia. J Soc Gynecol Investig 10:154–157PubMedCrossRef

34.

Serrano NC, Casas JP, Díaz LA et al (2004) Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case–control study. Hypertension 44:702–707PubMedCrossRef

35.

Sandrim VC, Palei AC, Cavalli RC et al (2008) eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9:1467–1473PubMedCrossRef

36.

Heiskanen J, Romppanen EL, Hiltunen M et al (2002) Polymorphism in the tumor necrosis factor-alpha gene in women with preeclampsia. J Assist Reprod Genet 19:220–223PubMedCrossRef

37.

Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 7:265–268PubMedCrossRef

38.

Xu B, Thornton C, Tooher J et al (2009) Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol 36:839–842PubMedCrossRef

39.

Harskamp RE, Zeeman GG (2007) Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 334:291–295PubMedCrossRef

Title: Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study
Authors: Enrique Teran
Fernando Briones
Verónica Nicolalde
Sandra Vivero
Peter Chedraui
Faustino R. Pérez-López
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 4/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-012-2217-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study

Abstract

Aim

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2012

Selective and non-selective intrauterine growth restriction in twin pregnancies: high-risk factors and perinatal outcome

Perinatal correlates of delayed childbearing in a developing country

Application of 1.5 T magnetic resonance imaging in endometrial cancer

Ethnic disparity in spontaneous preterm birth and maternal pre-pregnancy body mass index

Giant cell tumour of the ovary in a 70-year-old nulliparous woman: a case report and review of literature

Submental lymph node metastasis from invasive ductal breast carcinoma